benserazide has been researched along with Long Sleeper Syndrome in 6 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The putative role of the dopaminergic system in sleep bruxism (SB) was studied in a double-blind clinical trial by using low doses of short-term L-dopa in combination with benserazide." | 5.08 | The effect of catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial. ( Lavigne, GJ; Lobbezoo, F; Montplaisir, JY; Tanguay, R, 1997) |
| "The treatment of patients suffering from idiopathic Parkinson's disease has become more and more complex." | 2.43 | [Idiopathic Parkinson's disease: practical hints for the treatment]. ( Ludin, HP, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 1 |
| Yang, MH | 1 |
| Li, SD | 1 |
| Liu, Y | 1 |
| Ludin, HP | 1 |
| Linazasoro, G | 1 |
| Martí Massó, JF | 1 |
| Suárez, JA | 1 |
| Trenkwalder, C | 1 |
| Stiasny, K | 1 |
| Pollmächer, T | 1 |
| Wetter, T | 1 |
| Schwarz, J | 1 |
| Kohnen, R | 1 |
| Kazenwadel, J | 1 |
| Krüger, HP | 1 |
| Ramm, S | 1 |
| Künzel, M | 1 |
| Lobbezoo, F | 1 |
| Lavigne, GJ | 1 |
| Tanguay, R | 1 |
| Montplaisir, JY | 1 |
| Tissot, R | 1 |
| Bartholini, G | 1 |
| Constantinidis, J | 1 |
| Eisenring, JJ | 1 |
| Geissbühler, F | 1 |
| Yanniotis, G | 1 |
| de Ajuriaguerra, J | 1 |
1 review available for benserazide and Long Sleeper Syndrome
| Article | Year |
|---|---|
[Idiopathic Parkinson's disease: practical hints for the treatment].
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Benserazide; Choline | 2005 |
3 trials available for benserazide and Long Sleeper Syndrome
| Article | Year |
|---|---|
[Effects of bushenhuoxue granules on sleep quality in Parkinson's patients].
Topics: Aged; Aged, 80 and over; Benserazide; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; | 2011 |
L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Double-Blind Method; Drug Therap | 1995 |
The effect of catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial.
Topics: Adult; Benserazide; Bruxism; Cross-Over Studies; Dopamine Agents; Dose-Response Relationship, Drug; | 1997 |
2 other studies available for benserazide and Long Sleeper Syndrome
| Article | Year |
|---|---|
Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carbidopa; Circadian Rhythm; Clozapine; Confusion; Dose | 1993 |
[Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
Topics: Aged; Benserazide; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; Drug Evaluation; Drug Therapy | 1973 |